GERD market size to increase by USD 908.49 million; North America to account for 38% of market growth - Technavio

PR Newswire
Wednesday, January 25, 2023 at 2:15am UTC

GERD market size to increase by USD 908.49 million; North America to account for 38% of market growth - Technavio

PR Newswire

NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The GERD Market by Route of Administration, Type, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 908.49 million between 2022 and 2027 at a CAGR of 3.4%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download A PDF Sample Report

Regional Analysis

By region, the global GERD market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 38% of market growth during the forecast period. Factors such as the increasing preference for OTC medications and the practice of self-medication among the population are driving the growth of the GERD market in North America. Buy the report

Company Profiles

The GERD market report includes information on the key products and recent developments of leading vendors, including:

  • Bayer AG - The company offers GERD drugs such as abbott pantoprazole.
  • Alkem Laboratories Ltd. - The company offers GERD drugs such as esokem and omee.
  • Apotex Inc. - The company offers GERD drugs such as famotidine.
  • AstraZeneca Plc - The company offers GERD drugs such as nexium 20 mg.

Market Dynamics

The market is driven by factors such as the rising geriatric population, poor lifestyle patterns, and the overuse of medicines and dietary supplements. However, the increasing preference for complementary and alternative medicine CAM is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample

Market Segmentation

  • By administration, the market is segmented into oral and parenteral. The oral segment accounted for the largest share of the market in 2022.
  • By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market in 2022.

Related Reports:

  • The human combination vaccines market is estimated to grow at a CAGR of 8.13% between 2022 and 2027. The size of the market is forecast to increase by USD 6,046.98 million. The rise in cases of infectious diseases notably drives the market growth, although factors such as the incompatibility of vaccine components may impede the market growth.
  • The nutrition market is estimated to grow at a CAGR of 4.48% between 2022 and 2027. The size of the market is forecast to increase by USD 34.79 billion. The growing geriatric population is notably driving the market growth, although factors such as product recalls may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging
technologies.
Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to
Technavio Insights

What are the key data covered in this GERD market report?

  • CAGR of the market during the forecast period.
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the size of the GERD market and its contribution to the parent market.
  • Accurate predictions about upcoming trends and changes in consumer behavior.
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW).
  • A thorough analysis of the market's competitive landscape and detailed information about vendors.
  • Comprehensive analysis of factors that will challenge the growth of GERD market vendors.

GERD Market Scope

Report Coverage

Details

Page number

166

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 3.4%

Market growth 2023-2027

USD 908.49 million

Market structure

Fragmented

YoY growth 2022-2023(%)

3.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Bayer AG, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, iNova Pharmaceuticals, Johnson and Johnson, Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., The Procter and Gamble Co., and Abbott Laboratories

Market dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027 
    • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global GERD market 2017 - 2021 
    • Exhibit 18: Historic Market Size – Data Table on Global GERD market 2017 - 2021 ($ million)
  • 4.2 Route of Administration Segment Analysis 2017 - 2021 
    • Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)
  • 4.3 Drug Type Segment Analysis 2017 - 2021 
    • Exhibit 20: Historic Market Size – Drug Type Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021 
    • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021 
    • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
    • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers 
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers 
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants 
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes 
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition
    • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

  • 6.1 Market segments
    • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
  • 6.2 Comparison by Route of Administration 
    • Exhibit 32: Chart on Comparison by Route of Administration
    • Exhibit 33: Data Table on Comparison by Route of Administration
  • 6.3 Oral - Market size and forecast 2022-2027 
    • Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
    • Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
    • Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
  • 6.4 Parenteral - Market size and forecast 2022-2027 
    • Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
    • Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
    • Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Route of Administration 
    • Exhibit 42: Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
    • Exhibit 43: Chart on Type - Market share 2022-2027 (%)
    • Exhibit 44: Data Table on Type - Market share 2022-2027 (%)
  • 7.2 Comparison by Type
    • Exhibit 45: Chart on Comparison by Type
    • Exhibit 46: Data Table on Comparison by Type
  • 7.3 Antacid - Market size and forecast 2022-2027 
    • Exhibit 47: Chart on Antacid - Market size and forecast 2022-2027 ($ million)
    • Exhibit 48: Data Table on Antacid - Market size and forecast 2022-2027 ($ million)
    • Exhibit 49: Chart on Antacid - Year-over-year growth 2022-2027 (%)
    • Exhibit 50: Data Table on Antacid - Year-over-year growth 2022-2027 (%)
  • 7.4 PPI - Market size and forecast 2022-2027 
    • Exhibit 51: Chart on PPI - Market size and forecast 2022-2027 ($ million)
    • Exhibit 52: Data Table on PPI - Market size and forecast 2022-2027 ($ million)
    • Exhibit 53: Chart on PPI - Year-over-year growth 2022-2027 (%)
    • Exhibit 54: Data Table on PPI - Year-over-year growth 2022-2027 (%)
  • 7.5 H2 receptor antagonist drugs - Market size and forecast 2022-2027 
    • Exhibit 55: Chart on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
    • Exhibit 56: Data Table on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
    • Exhibit 57: Chart on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
    • Exhibit 58: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
  • 7.6 Pro-Kinetic drugs - Market size and forecast 2022-2027 
    • Exhibit 59: Chart on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
    • Exhibit 60: Data Table on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
    • Exhibit 61: Chart on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
    • Exhibit 62: Data Table on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Type 
    • Exhibit 63: Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview 
    • Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation 
    • Exhibit 65: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison 
    • Exhibit 67: Chart on Geographic comparison
    • Exhibit 68: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027 
    • Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
    • Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027 
    • Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
    • Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027 
    • Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
    • Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
    • Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027 
    • Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
    • Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027 
    • Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
    • Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 UK - Market size and forecast 2022-2027 
    • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
    • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.10 China - Market size and forecast 2022-2027 
    • Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
    • Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.11 Canada - Market size and forecast 2022-2027 
    • Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
    • Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
    • Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
    • Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography 
    • Exhibit 105: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges 
    • Exhibit 106: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
    • Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
    • Exhibit 108: Overview on factors of disruption
  • 11.4 Industry risks
    • Exhibit 109: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
    • Exhibit 110: Vendors covered
  • 12.2 Market positioning of vendors 
    • Exhibit 111: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories
    • Exhibit 112: Abbott Laboratories - Overview
    • Exhibit 113: Abbott Laboratories - Business segments
    • Exhibit 114: Abbott Laboratories - Key news
    • Exhibit 115: Abbott Laboratories - Key offerings
    • Exhibit 116: Abbott Laboratories - Segment focus
  • 12.4 Alkem Laboratories Ltd. 
    • Exhibit 117: Alkem Laboratories Ltd. - Overview
    • Exhibit 118: Alkem Laboratories Ltd. - Business segments
    • Exhibit 119: Alkem Laboratories Ltd. - Key news
    • Exhibit 120: Alkem Laboratories Ltd. - Key offerings
    • Exhibit 121: Alkem Laboratories Ltd. - Segment focus
  • 12.5 Apotex Inc.
    • Exhibit 122: Apotex Inc. - Overview
    • Exhibit 123: Apotex Inc. - Product / Service
    • Exhibit 124: Apotex Inc. - Key offerings
  • 12.6 AstraZeneca Plc
    • Exhibit 125: AstraZeneca Plc - Overview
    • Exhibit 126: AstraZeneca Plc - Product / Service
    • Exhibit 127: AstraZeneca Plc - Key news
    • Exhibit 128: AstraZeneca Plc - Key offerings
  • 12.7 Aurobindo Pharma Ltd. 
    • Exhibit 129: Aurobindo Pharma Ltd. - Overview
    • Exhibit 130: Aurobindo Pharma Ltd. - Product / Service
    • Exhibit 131: Aurobindo Pharma Ltd. - Key offerings
  • 12.8 Bayer AG
    • Exhibit 132: Bayer AG - Overview
    • Exhibit 133: Bayer AG - Business segments
    • Exhibit 134: Bayer AG - Key news
    • Exhibit 135: Bayer AG - Key offerings
    • Exhibit 136: Bayer AG - Segment focus
  • 12.9 Cipla Ltd.
    • Exhibit 137: Cipla Ltd. - Overview
    • Exhibit 138: Cipla Ltd. - Business segments
    • Exhibit 139: Cipla Ltd. - Key news
    • Exhibit 140: Cipla Ltd. - Key offerings
    • Exhibit 141: Cipla Ltd. - Segment focus
  • 12.10 Dr Reddys Laboratories Ltd. 
    • Exhibit 142: Dr Reddys Laboratories Ltd. - Overview
    • Exhibit 143: Dr Reddys Laboratories Ltd. - Business segments
    • Exhibit 144: Dr Reddys Laboratories Ltd. - Key offerings
    • Exhibit 145: Dr Reddys Laboratories Ltd. - Segment focus
  • 12.11 Eisai Co. Ltd.
    • Exhibit 146: Eisai Co. Ltd. - Overview
    • Exhibit 147: Eisai Co. Ltd. - Business segments
    • Exhibit 148: Eisai Co. Ltd. - Key offerings
    • Exhibit 149: Eisai Co. Ltd. - Segment focus
  • 12.12 Fresenius SE and Co. KGaA 
    • Exhibit 150: Fresenius SE and Co. KGaA - Overview
    • Exhibit 151: Fresenius SE and Co. KGaA - Business segments
    • Exhibit 152: Fresenius SE and Co. KGaA - Key news
    • Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
    • Exhibit 154: Fresenius SE and Co. KGaA - Segment focus
  • 12.13 GlaxoSmithKline Plc
    • Exhibit 155: GlaxoSmithKline Plc - Overview
    • Exhibit 156: GlaxoSmithKline Plc - Business segments
    • Exhibit 157: GlaxoSmithKline Plc - Key offerings
    • Exhibit 158: GlaxoSmithKline Plc - Segment focus
  • 12.14 iNova Pharmaceuticals 
    • Exhibit 159: iNova Pharmaceuticals - Overview
    • Exhibit 160: iNova Pharmaceuticals - Product / Service
    • Exhibit 161: iNova Pharmaceuticals - Key offerings
  • 12.15 Johnson and Johnson
    • Exhibit 162: Johnson and Johnson - Overview
    • Exhibit 163: Johnson and Johnson - Business segments
    • Exhibit 164: Johnson and Johnson - Key news
    • Exhibit 165: Johnson and Johnson - Key offerings
    • Exhibit 166: Johnson and Johnson - Segment focus
  • 12.16 Lupin Ltd.
    • Exhibit 167: Lupin Ltd. - Overview
    • Exhibit 168: Lupin Ltd. - Product / Service
    • Exhibit 169: Lupin Ltd. - Key news
    • Exhibit 170: Lupin Ltd. - Key offerings
  • 12.17 Perrigo Co. Plc
    • Exhibit 171: Perrigo Co. Plc - Overview
    • Exhibit 172: Perrigo Co. Plc - Business segments
    • Exhibit 173: Perrigo Co. Plc - Key news
    • Exhibit 174: Perrigo Co. Plc - Key offerings
    • Exhibit 175: Perrigo Co. Plc - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist 
    • Exhibit 176: Inclusions checklist
    • Exhibit 177: Exclusions checklist
  • 13.3 Currency conversion rates for US$ 
    • Exhibit 178: Currency conversion rates for US$
  • 13.4 Research methodology
    • Exhibit 179: Research methodology
    • Exhibit 180: Validation techniques employed for market sizing
    • Exhibit 181: Information sources
  • 13.5 List of abbreviations 
    • Exhibit 182: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gerd-market-size-to-increase-by-usd-908-49-million-north-america-to-account-for-38-of-market-growth---technavio-301728015.html

SOURCE Technavio